iHealthScreen, an artificial intelligence (“AI”)-based health-screening company, announced that it has raised $150,000 on StartEngine. An AI-driven, HIPAA-compliant medtech company, iHealthScreen uses AI to screen for retinal diseases, stroke and heart disease and prevent blindness, deaths and disabilities. In addition to the $150,000 raised on StartEngine, iHealthScreen has raised more than $3 million in seed and NIH funding. The company offers investors a unique opportunity to capitalize on AI-driven, health-screening software developed by medical professionals. According to the company, testing for certain diseases and conditions can be cost prohibitive, and primary care providers often don’t have resources to do more than basic screenings. iHealthScreen has developed a fast, low-cost solution for eye-disease screening. The company has raised $750,000 in seed funding and been awarded an additional $2.7 million in NIH funding; the company is also working to secure additional research grant funding. “This integrated, retinal imaging-based system is unprecedented in the surgical robotics industry,” the company stated in the press release. “iHealthScreen is the first company in the world to receive CE certification and Australian and UAE health approvals for age-related macular degeneration (‘AMD’), diabetic retinopathy (‘DR’) and glaucoma screening. Additionally, hospitals aren’t required for the company’s surgical robotics to be used; its systems can be incorporated into primary care provider facilities at the local level.”
To view the full press release, visit https://ibn.fm/vMlgN
About iHealthScreen
iHealthScreen offers an integrated, retinal imaging-based system. The company is one of the first in the world to receive CE certification as well as Australian and UAE health approvals for AMD, DR and glaucoma screening. The company is gaining international traction with contracts in the United States, European Union, Bangladesh and UAE. iHealthScreen has also been collaborating with Global Victoria in Australia. For more information about the company, please visit www.StartEngine.com/offering/iHealthScreen.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
